Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7320872 | 0.95 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL10538464 | 0.93 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL7314532 | 0.93 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL864488 | 0.89 | L3MBTL3 (0.40) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL863893 | 0.87 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL1800599 | 0.82 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1TP53BP1HRH3 | |
| SCHEMBL6628090 | 0.80 | OPRM1 (0.43) | L3MBTL3L3MBTL1HRH3 | |
| SCHEMBL4213726 | 0.80 | MAPK1 (0.43) | L3MBTL3L3MBTL1TP53BP1TRIM24TRIM33 | |
| SCHEMBL9998713 | 0.79 | ALDH1A1 (0.35) | L3MBTL1TRIM24TRIM33HRH3 | |
| SCHEMBL3880193 | 0.79 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3682881-B1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-12297187-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-111094255-B | Compounds having cyclic structures | 第一三共株式会社 | 2023-10-03 | — | — | CN | disclosed |
| US-11512067-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-11-29 | — | — | US | disclosed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3682881-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-22 | — | — | EP | disclosed |
| EP-3682881-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094255-A | Compound having cyclic structure | 第一三共株式会社 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019054427-A1 | COMPOUND HAVING CYCLIC STRUCTURE | 第一三共株式会社 | 2019-03-21 | — | — | WO | disclosed |
| WO-2018086589-A1 | 1,5,7-TRI-SUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES | 上海海雁医药科技有限公司 | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297187-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | L3MBTL3 3956/4885L3MBTL1 3800/4885MBTD1 4110/4885 |
| US-20200347030-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | L3MBTL3 3956/4885L3MBTL1 3800/4885MBTD1 4110/4885 |
| US-11512067-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | L3MBTL3 3956/4885L3MBTL1 3800/4885MBTD1 4110/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | L3MBTL3 3956/4885L3MBTL1 3800/4885MBTD1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.